Related Practice Life Sciences & Pharma Unlike many other markets in the world, Japan had until very recently been driven by ‘share-of-voice’, with market development and patient share being largely sensitive to sales activity. 02172021150243
Published Articles Mental and Behavioral Health Trip or No Trip? The Diverging Development of Psychedelic Drugs for Mental Health … December 15, 2022
Article Mental and Behavioral Health A Test of Resilience: Looking Forward to Psychedelics Funding in 2023 March 7, 2023
Special Report Life Sciences & Pharma Viral-Based Gene Therapy: Key Challenges and Bioprocessing Innovations December 16, 2022
Podcast Biotech and Pharmaceuticals Five Essential Factors for a Successful Biopharma Product Launch March 23, 2023
Executive Insights Healthcare Services Scaling Digital Health in APAC — Key Trends and Challenges January 19, 2023